SCHEMBL22495255

SCHEMBL22495255

N#Cc1ccc(N2CCN(c3ccc(NC(=O)c4ccc(OCCF)cc4)cc3)CC2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 12/20 0.62
HSD17B10 Q99714 4/20 0.62
HPGD P15428 2/20 0.62
TSHR P16473 2/20 0.62
TAAR1 Q96RJ0 1/20 0.62
ALDH1A1 P00352 7/20 0.60
SMN1; SMN2 Q16637 4/20 0.60
USP2 O75604 2/20 0.60
HIF1A Q16665 1/20 0.60
KMT2A Q03164 6/20 0.58
MEN1 O00255 3/20 0.58
KDM4E B2RXH2 3/20 0.58
LMNA P02545 1/20 0.58
ALOX15 P16050 2/20 0.57
NPSR1 Q6W5P4 1/20 0.53
RXFP1 Q9HBX9 1/20 0.53
RAB9A P51151 2/20 0.53
NPC1 O15118 1/20 0.53
NR4A1 P22736 1/20 0.52
MCL1 Q07820 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22495387 0.94 MAPT (0.58) MAPTHSD17B10HPGDTSHRTAAR1
SCHEMBL22495260 0.94 MAPT (0.58) MAPTHSD17B10HPGDTSHRTAAR1
SCHEMBL22495249 0.90 MAPT (0.54) MAPTHSD17B10HPGDTSHRTAAR1
SCHEMBL31504202 0.90 MAPT (0.54) MAPTHSD17B10HPGDTSHRTAAR1
SCHEMBL31504253 0.85 KMT2A (0.54) MAPTHSD17B10HPGDTSHRTAAR1
SCHEMBL22495263 0.85 KMT2A (0.54) MAPTHSD17B10HPGDTSHRTAAR1
SCHEMBL22523833 0.85 MLYCD (0.54) MAPTHSD17B10TSHRALDH1A1SMN1; SMN2
SCHEMBL22495274 0.85 MAPT (0.51) MAPTHSD17B10HPGDTSHRTAAR1
SCHEMBL28453259 0.84 MAPT (0.61) MAPTHSD17B10HPGDTSHRTAAR1
SCHEMBL22495460 0.84 RAB9A (0.74) MAPTHSD17B10HPGDTSHRTAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3728234-B1 RADIOLABELED COMPOUNDS HOFFMANN LA ROCHE (CH) 2025-05-14 EP claimed
US-11541132-B2 Radiolabeled compounds HOFFMANN-LA ROCHE INC. (US) 2023-01-03 US claimed
EP-3728234-A1 RADIOLABELED COMPOUNDS F. Hoffmann-La Roche AG (CH) 2020-10-28 EP claimed
US-20200316232-A1 RADIOLABELED COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2020-10-08 US claimed
CN-111511732-A Radiolabelled compounds 豪夫迈·罗氏有限公司 2020-08-07 CN claimed
EP-3728234-B1 RADIOLABELED COMPOUNDS HOFFMANN LA ROCHE (CH) 2025-05-14 EP disclosed
US-11541132-B2 Radiolabeled compounds HOFFMANN-LA ROCHE INC. (US) 2023-01-03 US disclosed
US-11541132-B2 Radiolabeled compounds HOFFMANN-LA ROCHE INC. (US) 2023-01-03 US disclosed
EP-3728234-A1 RADIOLABELED COMPOUNDS F. Hoffmann-La Roche AG (CH) 2020-10-28 EP disclosed
US-20200316232-A1 RADIOLABELED COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2020-10-08 US disclosed
US-20200316232-A1 RADIOLABELED COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2020-10-08 US disclosed
CN-111511732-A Radiolabelled compounds 豪夫迈·罗氏有限公司 2020-08-07 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11541132-B2 Radiolabeled compounds SNCA, APP, BACE1 MAPT 16/4885HSD17B10 2980/4885HPGD 3605/4885
US-20200316232-A1 RADIOLABELED COMPOUNDS SNCA, APP, BACE1 MAPT 17/4885HSD17B10 3169/4885HPGD 3645/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.